Computational models of antiviral toxicity

Current Opinion in Drug Discovery and Development

Volumn 10, Issue 1, 2007, Pages 43-48

  Samuels, David C ^a  

^a VIRGINIA BIOINFORMATICS INSTITUTE   (United States)

Author keywords

Antiretroviral toxicity; AZT; d4T; Mitochondrial toxicity; Nucleoside analog; Polymerase

Indexed keywords

1 (2 PHOSPHONOMETHOXYCYCLOPENTYL)URACIL; 1 [2' DEOXY 3',5' O (1 PHOSPHONO)BENZYLIDENE BETA DEXTRO THREO PENTOFURANOSYL]THYMINE; 5 (2 BROMOVINYL) 2' DEOXYURIDINE PHOSPHATE; ANTIVIRUS AGENT; DEOXYCYTIDINE; DEOXYRIBONUCLEOTIDASE; DEOXYURIDINE PHOSPHATE; DNA POLYMERASE; FLOXURIDINE PHOSPHATE; LAMIVUDINE; MITOCHONDRIAL DNA; NUCLEOSIDE ANALOG; PRODRUG; STAVUDINE; THYMIDINE PHOSPHATE; THYMIDINE TRIPHOSPHATE; UNCLASSIFIED DRUG; ZIDOVUDINE;

CONFERENCE PAPER; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG STRUCTURE; EXPERIMENTAL STUDY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MITOCHONDRIAL TOXICITY; MOLECULAR MODEL; NUCLEOTIDE SEQUENCE; VIRUS LOAD;

ANTI-HIV AGENTS; COMPUTER SIMULATION; DRUG TOXICITY; HIV INFECTIONS; HUMANS; LAMIVUDINE; MOLECULAR STRUCTURE; STAVUDINE; ZIDOVUDINE;

EID: 33947396822     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (56)

1. De Clercq E: Antiviral drugs in current clinical use. J Clin Virol (2004) 30(2):115-133. • A thorough listing of clinically used antiviral drugs, covering antiviral agents for many viruses other than HIV.
2. Hammer SM, Saag MS, Schechter M, Montaner JS, Schooley RT, Jacobsen DM, Thompson MA, Carpenter CC, Fischl MA, Gazzard BG, Gatell JM et al: Treatment for adult HIV infection - 2006 recommendations of the International AIDS Society-USA panel. J Am Med Assoc (2006) 296(7):827-843. • The most current, authoritative and concise description of the recommended treatment for adult HIV infection.
3. Vivet-Boudou V, Didierjean J, Isel C, Marquet R: Nucleoside and nucleotide inhibitors of HIV-1 replication. Cell Mol Life Sci (2006) 63(2):163-186. • A wide ranging review of the currently used nucleoside and nucleotide analogs, along with interesting information on the viral resistance mechanisms that have been identified for each drug. Detailed discussions of new nucleoside analogs that are currently in clinical trials are included.
4. d'Arminio Monforte A, Lepri AC, Rezza G, Pezzotti P, Antinori A, Phillips AN, Angarano G, Colangeli V, De Luca A, Ippolito G et al: Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naive patients. Aids (2000) 14(5):499-507.
5. del Rio C: Current concepts in antiretroviral therapy failure. Topics HIV Med (2006) 14(3):102-106.
6. Fellay J, Boubaker K, Ledergerber B, Bernasconi E, Furrer H, Battegay M, Hirschel B, Vernazza P, Francioli P, Greub G, Flepp M et al: Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV cohort study. Lancet (2001) 358(9290):1322-1327.
7. Dagan T, Sable C, Bray J, Gerschenson M: Mitochondrial dysfunction and antiretroviral nucleoside analog toxicities: What is the evidence? Mitochondrion (2002) 1(5):397-412.
8. Day L, Shikuma C, Gerschenson M: Mitochondrial injury in the pathogenesis of antiretroviral-induced hepatic steatosis and lactic acidemia. Mitochondrion (2004) 4(2-3):95-109.
9. Feng JY, Johnson AA, Johnson KA, Anderson KS: Insights into the molecular mechanism of mitochondrial toxicity by AIDS drugs. J Biol Chem (2001) 276(26):23832-23837.
10. McComsey G, Lonergan JT: Mitochondrial dysfunction: Patient monitoring and toxicity management. J Acquir Immune Defic Syndr (2004) 37(Suppl 1):S30-S35.
11. McBride HM, Neuspiel M, Wasiak S: Mitochondria: More than just a powerhouse. Curr Biol (2006) 16(14):R551-R560. •• An excellent brief review of the broad range of cellular processes that involve mitochondria.
12. Pinti M, Salomoni P, Cossarizza A: Anti-HIV drugs and the mitochondria. Biochim Biophys Acta (2006) 1757(5-6):700-707.
13. Yap CW, Xue Y, Li H, Li ZR, Ung CY, Han LY, Zheng CJ, Cao ZW, Chen YZ: Prediction of compounds with specific pharmacodynamic, pharmacokinetic or toxicological property by statistical learning methods. Mini Rev Med Chem (2006) 6(4):449-459.
14. Ji ZL, Wang Y, Yu L, Han LY, Zheng CJ, Chen YZ: In silico search of putative adverse drug reaction related proteins as a potential tool for facilitating drug adverse effect prediction. Toxicol Lett (2006) 164(2):104-112.
15. Johnson DE, Rodgers AD: Computational toxicology: Heading toward more relevance in drug discovery and development. Curr Opin Drug Discovery Dev (2006) 9(1):29-37.
16. Li H, Yap CW, Xue Y, Li ZR, Ung CY, Han LY, Chen YZ: Statistical learning approach for predicting specific pharmacodynamic, pharmacokinetic, or toxicological properties of pharmaceutical agents. Drug Dev Res (2005) 66(4):245-259.
17. Mekenyan OG, Dimitrov SD, Pavlov TS, Veith GD: A systematic approach to simulating metabolism in computational toxicology. I. The TIMES heuristic modelling framework. Curr Pharm Design (2004) 10(11):1273- 1293.
18. Whittaker PA: What is the relevance of bioinformatics to pharmacology? Trends Pharmacol Sci (2003) 24(8):434-439.
19. Ekins S: In silico approaches to predicting drug metabolism, toxicology and beyond. Biochem Soc Trans (2003) 31(Pt 3):611-614.
20. Conolly RB: The use of biologically based modeling in risk assessment. Toxicology (2002) 181-182:275-279.
21. Fielden MR, Matthews JB, Fertuck KC, Halgren RG, Zacharewski TR: In silico approaches to mechanistic and predictive toxicology: An introduction to bioinformatics for toxicologists. Crit Rev Toxicol (2002) 32(2):67-112.
22. el-Masri HA, Mumtaz MM, Choudhary G, Cibulas W, De Rosa CT: Applications of computational toxicology methods at the agency for toxic substances and disease registry. Int J Hyg Environ Health (2002) 205(1-2):63-69.
23. Sello G, Sala L, Benfenati E: Predicting toxicity: A mechanism of action model of chemical mutagenicity. Mutat Res Fundam Mol Mech Mutagen (2001) 479(1-2):141-171.
24. Barratt MD, Rodford RA: The computational prediction of toxicity. Curr Opin Chem Biol (2001) 5(4):383-388.
25. Matthews EJ, Kruhlak NL, Cimino MC, Benz RD, Contrera JF: An analysis of genetic toxicity, reproductive and developmental toxicity, and carcinogenicity data: II. Identification of genotoxicants, reprotoxicants, and carcinogens using in silico methods. Regul Toxicol Pharmacol (2006) 44(2):97-110.
26. Simon-Hettich B, Rothfuss A, Steger-Hartmann T: Use of computer-assisted prediction of toxic effects of chemical substances. Toxicology (2006) 224(1-2):156-162.
27. Barratt MD: Prediction of toxicity from chemical structure. Cell Biol Toxicol (2000) 16(1):1-13.
28. Lim SE, Copeland WC: Differential incorporation and removal of antiviral deoxynucleotides by human DNA polymerase γ. J Biol Chem (2001) 276(26):23616-23623.
29. Lim SE, Ponamarev MV, Longley MJ, Copeland WC: Structural determinants in human DNA polymerase γ account for mitochondrial toxicity from nucleoside analogs. J Mol Biol (2003) 329(1):45-57. •• This paper reports on measured kinetic parameter values for many nucleoside analogs as substrates for polymerase γ.
30. Lewis W, Kohler JJ, Hosseini SH, Haase CP, Copeland WC, Bienstock RJ, Ludaway T, McNaught J, Russ R, Stuart T, Santoianni R: Antiretroviral nucleosides, deoxynucleotide carrier and mitochondrial DNA: Evidence supporting the DNA pol γ hypothesis. Aids (2006) 20(5):675-684. •• This paper covers an exceptionally wide range of evidence for nucleoside analog toxicity.
31. Bienstock RJ, Copeland WC: Molecular insights into NRTI inhibition and mitochondrial toxicity revealed from a structural model of the human mitochondrial DNA polymerase. Mitochondrion (2004) 4(2-3):203-213.
32. Graziewicz MA, Longley MJ, Bienstock RJ, Zeviani M, Copeland WC: Structure-function defects of human mitochondrial DNA polymerase in autosomal dominant progressive external ophthalmoplegia. Nat Struct Mol Biol (2004) 11(8):770-776.
33. Anderson PL, Kakuda TN, Lichtenstein KA: The cellular pharmacology of nucleoside- and nucleotide-analogue reverse-transcriptase inhibitors and its relationship to clinical toxicities. Clin Infect Dis (2004) 38(5):743-753.
34. Mazzon C, Rampazzo C, Scaini MC, Gallinaro L, Karlsson A, Meier C, Balzarini J, Reichard P, Bianchi V: Cytosolic and mitochondrial deoxyribonucleotidases: Activity with substrate analogs, inhibitors and implications for therapy. Biochem Pharmacol (2003) 66(3):471-479. •• This paper reports on the dephosphorylation activity of both the human mitochondrial and cytoplasmic deoxyribonucleotidases for 17 substrates, allowing for a consistent and easy comparison across several important antiviral agents.
35. Sales SD, Hoggard PG, Sunderland D, Khoo S, Hart CA, Back DJ: Zidovudine phosphorylation and mitochondrial toxicity in vitro. Toxicol Appl Pharmacol (2001) 177(1):54-58.
36. Himo F, Guo JD, Rinaldo-Matthis A, Nordlund P: Reaction mechanism of deoxyribonucleotidase: A theoretical study. J Phys Chem B Condens Matter Mater Surf Interface Biophys (2005) 109(42):20004-20008.
37. Rinaldo-Matthis A, Rampazzo C, Balzarini J, Reichard P, Bianchi V, Nordlund P: Crystal structures of the mitochondrial deoxyribonucleotidase in complex with two specific inhibitors. Mol Pharmacol (2004) 65(4):860-867.
38. Rinaldo-Matthis A, Rampazzo C, Reichard P, Bianchi V, Nordlund P: Crystal structure of a human mitochondrial deoxyribonucleotidase. Nat Struct Biol (2002) 9(10):779-787.
39. Wallden K, Ruzzenente B, Rinaldo-Matthis A, Bianchi V, Nordlund P: Structural basis for substrate specificity of the human mitochondrial deoxyribonucleotidase. Structure (2005) 13(7):1081-1088.
40. Piliero PJ: Pharmacokinetic properties of nucleoside/nucleotide reverse transcriptase inhibitors. J Acquir Immune Defic Syndr (2004) 37(Suppl 1):S2-S12.
41. Samuels DC: Mitochondrial AZT metabolism. IUBMB Life (2006) 58(7):403-408.
42. Zhou Z, Rodman JH, Flynn PM, Robbins BL, Wilcox CK, D'Argenio DZ: Model for intracellular lamivudine metabolism in peripheral blood mononuclear cells ex vivo and in human immunodeficiency virus type 1-infected adolescents. Antimicrob Agents Chemother (2006) 50(8):2686-2694.
43. Bradshaw PC, Samuels DC: A computational model of mitochondrial deoxynucleotide metabolism and DNA replication. Am J Physiol - Cell Physiol (2005) 288(5):C989-C1002.
44. Bradshaw PC, Li JX, Samuels DC: A computational model of mitochondrial AZT metabolism. Biochem J (2005) 392(Pt 2):363-373.
45. Piko L, Bulpitt KJ, Meyer R: Structural and replicative forms of mitochondrial-DNA in tissues from adult and senescent BALB/c mice and Fischer 344 rats. Mech Ageing Dev (1984) 26(1):113-131.
46. Lewis W, Copeland WC, Day BJ: Mitochondrial DNA depletion, oxidative stress, and mutation: Mechanisms of dysfunction from nucleoside reverse transcriptase inhibitors. Lab Invest (2001) 81(6):777-790.
47. Carr A, Cooper DA: Adverse effects of antiretroviral therapy. Lancet (2000) 356(9239):1423-1430.
48. Mathews CK: DNA precursor metabolism and genomic stability. FASEB J (2006) 20(9):1300-1314.
49. Andersen ME, Thomas RS, Gaido KW, Conolly RB: Dose-response modeling in reproductive toxicology in the systems biology era. Reprod Toxicol (2005) 19(3):327-337.
50. Cummings A, Kavlock R: A systems biology approach to developmental toxicology. Reprod Toxicol (2005) 19(3):281-290.
51. Kriete A, Boyce K, Love B: System-wide analysis of hepatotoxicological responses: Tissomics is key. Cytometry Pt A (2006) 69(7):612-619.
52. Slikker W, Xu Z, Wang C: Application of a systems biology approach to developmental neurotoxicology. Reprod Toxicol (2005) 19(3):305-319.
53. Ekins S, Andreyev S, Ryabov A, Kirillov E, Rakhmatulin EA, Sorokina S, Bugrim A, Nikolskaya T: A combined approach to drug metabolism and toxicity assessment. Drug Metab Dispos (2006) 34(3):495-503.
54. Ekins S, Nikolsky Y, Nikolskaya T: Techniques: Application of systems biology to absorption, distribution, metabolism, excretion and toxicity. Trends Pharmacol Sci (2005) 26(4):202-209.
55. Mayne JT, Ku WW, Kennedy SP: Informed toxicity assessment in drug discovery: Systems-based toxicology. Curr Opin Drug Discovery Dev (2006) 9(1):75-83.
56. Xirasagar S, Gustafson SF, Huang CC, Pan Q, Fostel J, Boyer P, Merrick BA, Tomer KB, Chan DD, Yost KJ 3rd, Choi D et al: Chemical effects in biological systems (CEBS) object model for toxicology data, SysTox-OM: Design and application. Bioinformatics (2006) 22(7):874-882.